HIV-1 Dynamics in Vivo: Virion Clearance Rate, Infected Cell Life-Span, and Viral Generation Time

American Association for the Advancement of Science (AAAS) - Tập 271 Số 5255 - Trang 1582-1586 - 1996
Alan S. Perelson1, Avidan U. Neumann1, Martin Markowitz2, John M. Leonard3, David D. Ho2
1A. S. Perelson and A. U. Neumann, Theoretical Division, Los Alamos National Laboratory, Los Alamos, NM 87545, USA.
2M. Markowitz and D. D. Ho, Aaron Diamond AIDS Research Center, 455 First Avenue, New York, NY 10016, USA.
3J. M. Leonard, Pharmaceutical Products Division, Abbott Laboratories, Abbott Park, IL 60064, USA.

Tóm tắt

A new mathematical model was used to analyze a detailed set of human immunodeficiency virus-type 1 (HIV-1) viral load data collected from five infected individuals after the administration of a potent inhibitor of HIV-1 protease. Productively infected cells were estimated to have, on average, a life-span of 2.2 days (half-life t 1/2 = 1.6 days), and plasma virions were estimated to have a mean life-span of 0.3 days ( t 1/2 = 0.24 days). The estimated average total HIV-1 production was 10.3 × 10 9 virions per day, which is substantially greater than previous minimum estimates. The results also suggest that the minimum duration of the HIV-1 life cycle in vivo is 1.2 days on average, and that the average HIV-1 generation time—defined as the time from release of a virion until it infects another cell and causes the release of a new generation of viral particles—is 2.6 days. These findings on viral dynamics provide not only a kinetic picture of HIV-1 pathogenesis, but also theoretical principles to guide the development of treatment strategies.

Từ khóa


Tài liệu tham khảo

CAO Y, CLINICAL-EVALUATION OF BRANCHED DNA SIGNAL AMPLIFICATION FOR QUANTIFYING HIV TYPE-1 IN HUMAN PLASMA, AIDS RESEARCH AND HUMAN RETROVIRUSES 11, 353 (1995).

CARMICHAEL A, QUANTITATIVE-ANALYSIS OF THE HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 (HIV-1)-SPECIFIC CYTOTOXIC LYMPHOCYTE-T (CTL) RESPONSE AT DIFFERENT STAGES OF HIV-1 INFECTION - DIFFERENTIAL CTL RESPONSES TO HIV-1 AND EPSTEIN-BARR-VIRUS IN LATE DISEASE, JOURNAL OF EXPERIMENTAL MEDICINE 177, 249 (1993).

10.1126/science.7824947

EFRON B, STAT SCI 1, 54 (1986).

10.1038/373123a0

HO D. D., QUANTITATION OF HUMAN IMMUNODEFICIENCY VIRUS TYPE-1 IN THE BLOOD OF INFECTED PERSONS, NEW ENGLAND JOURNAL OF MEDICINE 321, 1621 (1989).

HO D. D., TIME TO HIT HIV, EARLY AND HARD, NEW ENGLAND JOURNAL OF MEDICINE 333, 450 (1995).

KEMPF J. D., ABT-538 IS A POTENT INHIBITOR OF HUMAN-IMMUNODEFICIENCY-VIRUS PROTEASE AND HAS HIGH ORAL BIOAVAILABILITY IN HUMANS, PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA 92, 2484 (1995).

MANSKY M. L., LOWER IN-VIVO MUTATION-RATE OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 THAN THAT PREDICTED FROM THE FIDELITY OF PURIFIED REVERSE-TRANSCRIPTASE, JOURNAL OF VIROLOGY 69, 5087 (1995).

MARKOWITZ M, A PRELIMINARY-STUDY OF RITONAVIR, AN INHIBITOR OF HIV-1 PROTEASE, TO TREAT HIV-1 INFECTION, NEW ENGLAND JOURNAL OF MEDICINE 333, 1534 (1995).

NATHANSON N, AM J EPIDEMIOL 85, 494 (1966).

NOWAK A. M., HIV RESULTS IN THE FRAME - RESULTS CONFIRMED, NATURE 375, 193 (1995).

PACHL C, RAPID AND PRECISE QUANTIFICATION OF HIV-1 RNA IN PLASMA USING A BRANCHED DNA SIGNAL AMPLIFICATION ASSAY, JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES AND HUMAN RETROVIROLOGY 8, 446 (1995).

WEI X, VIRAL DYNAMICS IN HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 INFECTION, NATURE 373, 117 (1995).

WINSLOW L. D., AIDS SA 9, S183 (1995).

Thông tin
Thông tin xuất bản

American Association for the Advancement of Science (AAAS)

Tập 271 Số 5255

1582-1586

Thông tin tác giả